We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Expressed in all
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Selective cytoplasmic expression in several tissues, most abundant in lymphoid tissues.
IMMUNOHISTOCHEMISTRY DATA RELIABILITY
Data reliability descriptioni
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Weak to moderate cytoplasmic immunoreactivity was observed in malignant lymphomas and tumors of cervix, pancreas, stomach, testis and ovary. Remaining tissues were in general negative.
Rare nuclear and cytoplasmic positivity were seen in cases of lung, gliomas and prostate cancer. Remaining cancers were weakly stained or negative.
Weak to moderate cytoplasmic and in few cases also nuclear positivity was found in several cancer tissues. Rare lymphomas and testicular tumors displayed strong immunoreactivity.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
CASP3 (HGNC Symbol)
Synonyms
apopain, CPP32, CPP32B, Yama
Description
Caspase 3 (HGNC Symbol)
Entrez gene summary
This gene encodes a protein which is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6, 7 and 9, and the protein itself is processed by caspases 8, 9 and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease. Alternative splicing of this gene results in two transcript variants that encode the same protein. [provided by RefSeq, Jul 2008]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
CASP3-001
CASP3-002
CASP3-003
CASP3-004
CASP3-005
CASP3-006
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Hydrolases Peptidases Cysteine-type peptidases Predicted intracellular proteins Plasma proteins Cancer-related genes Candidate cancer biomarkers Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001666 [response to hypoxia] GO:0001782 [B cell homeostasis] GO:0002020 [protease binding] GO:0004190 [aspartic-type endopeptidase activity] GO:0004197 [cysteine-type endopeptidase activity] GO:0004861 [cyclin-dependent protein serine/threonine kinase inhibitor activity] GO:0005123 [death receptor binding] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006309 [apoptotic DNA fragmentation] GO:0006508 [proteolysis] GO:0006915 [apoptotic process] GO:0006919 [activation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0006974 [cellular response to DNA damage stimulus] GO:0007507 [heart development] GO:0007605 [sensory perception of sound] GO:0007611 [learning or memory] GO:0008233 [peptidase activity] GO:0008234 [cysteine-type peptidase activity] GO:0008635 [activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c] GO:0008656 [cysteine-type endopeptidase activator activity involved in apoptotic process] GO:0009411 [response to UV] GO:0009611 [response to wounding] GO:0009749 [response to glucose] GO:0010033 [response to organic substance] GO:0010038 [response to metal ion] GO:0010165 [response to X-ray] GO:0014070 [response to organic cyclic compound] GO:0016005 [phospholipase A2 activator activity] GO:0016241 [regulation of macroautophagy] GO:0016485 [protein processing] GO:0016787 [hydrolase activity] GO:0021766 [hippocampus development] GO:0030182 [neuron differentiation] GO:0030216 [keratinocyte differentiation] GO:0030218 [erythrocyte differentiation] GO:0030220 [platelet formation] GO:0030889 [negative regulation of B cell proliferation] GO:0031264 [death-inducing signaling complex] GO:0032025 [response to cobalt ion] GO:0032355 [response to estradiol] GO:0032403 [protein complex binding] GO:0032496 [response to lipopolysaccharide] GO:0034349 [glial cell apoptotic process] GO:0034612 [response to tumor necrosis factor] GO:0035094 [response to nicotine] GO:0035329 [hippo signaling] GO:0035556 [intracellular signal transduction] GO:0042060 [wound healing] GO:0042493 [response to drug] GO:0042542 [response to hydrogen peroxide] GO:0043029 [T cell homeostasis] GO:0043065 [positive regulation of apoptotic process] GO:0043066 [negative regulation of apoptotic process] GO:0043200 [response to amino acid] GO:0043525 [positive regulation of neuron apoptotic process] GO:0045121 [membrane raft] GO:0045165 [cell fate commitment] GO:0045736 [negative regulation of cyclin-dependent protein serine/threonine kinase activity] GO:0045786 [negative regulation of cell cycle] GO:0046007 [negative regulation of activated T cell proliferation] GO:0046677 [response to antibiotic] GO:0048011 [neurotrophin TRK receptor signaling pathway] GO:0051384 [response to glucocorticoid] GO:0051402 [neuron apoptotic process] GO:0071310 [cellular response to organic substance] GO:0071407 [cellular response to organic cyclic compound] GO:0097153 [cysteine-type endopeptidase activity involved in apoptotic process] GO:0097190 [apoptotic signaling pathway] GO:0097192 [extrinsic apoptotic signaling pathway in absence of ligand] GO:0097194 [execution phase of apoptosis] GO:0097200 [cysteine-type endopeptidase activity involved in execution phase of apoptosis]
Enzymes ENZYME proteins Hydrolases Peptidases Cysteine-type peptidases Predicted intracellular proteins Plasma proteins Cancer-related genes Candidate cancer biomarkers Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004190 [aspartic-type endopeptidase activity] GO:0004197 [cysteine-type endopeptidase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005737 [cytoplasm] GO:0005829 [cytosol] GO:0005886 [plasma membrane] GO:0006309 [apoptotic DNA fragmentation] GO:0006508 [proteolysis] GO:0006915 [apoptotic process] GO:0006919 [activation of cysteine-type endopeptidase activity involved in apoptotic process] GO:0008233 [peptidase activity] GO:0008234 [cysteine-type peptidase activity] GO:0008635 [activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c] GO:0008656 [cysteine-type endopeptidase activator activity involved in apoptotic process] GO:0016241 [regulation of macroautophagy] GO:0016787 [hydrolase activity] GO:0030182 [neuron differentiation] GO:0030216 [keratinocyte differentiation] GO:0030218 [erythrocyte differentiation] GO:0030220 [platelet formation] GO:0034612 [response to tumor necrosis factor] GO:0035329 [hippo signaling] GO:0043066 [negative regulation of apoptotic process] GO:0048011 [neurotrophin TRK receptor signaling pathway] GO:0097153 [cysteine-type endopeptidase activity involved in apoptotic process] GO:0097190 [apoptotic signaling pathway] GO:0097192 [extrinsic apoptotic signaling pathway in absence of ligand] GO:0097194 [execution phase of apoptosis] GO:0097200 [cysteine-type endopeptidase activity involved in execution phase of apoptosis]
The Human Protein Atlas project is funded
MENU
